New Astronomer CEO Addresses ‘Surreal' Reality After Coldplay Kiss Cam Concert Scandal
Former Astronomer CEO Andy Byron was caught on a "kiss cam" at a Coldplay concert with a company ... More employee who is not his wife. (Photo by) Getty Images
DeJoy, who was installed as interim CEO over the weekend, in a LinkedIn post Monday afternoon made his first public comments since the scandal sparked a social media frenzy.
DeJoy said Astronomer had received 'a level of media attention that few companies—let alone startups in our small corner of the data and AI world—ever encounter' in recent days, though he did not refer to Byron by name, nor did he specifically reference the Coldplay concert incident.
DeJoy said Astronomer is 'now a household name,' but he said he 'would never have wished for it to happen like this,' calling the heightened attention 'unusual and surreal for our team.'
In his post, DeJoy said Astronomer has 'never shied away from challenges' and said he would approach the role with a 'wholehearted commitment to taking care of our people and delivering for our customers,' thanking his team for its 'resilience.'
Before taking the interim CEO position, DeJoy, a co-founder of the company, served as its chief product officer.
Astronomer announced Saturday that Byron would step down from his role as CEO, stating the company's 'leaders are expected to set the standard in both conduct and accountability, and recently, that standard was not met.'
Byron resigned three days after he was caught on a 'kiss cam' at a Coldplay concert in Foxborough, Massachusetts, hugging Kristin Cabot, Astronomer's chief people officer, who is not his wife. Cabot is still listed as chief people officer on the company's leadership page, which now also reflects DeJoy's status as interim CEO. Once the camera cut to Byron and Cabot, Cabot broke free from his arms and covered her face as Byron moved out of frame. 'Either they're having an affair, or they're just very shy. I'm not quite sure what to do,' Coldplay's frontman Chris Martin said. The incident—viewed as a scandal that may have revealed an extramarital affair—quickly went viral on social media, sparking plenty of memes and parodies, as well as discussions about privacy. Byron has not yet commented following the incident, despite the spread of a fake statement in which he appeared to apologize and quote Coldplay lyrics. Astronomer confirmed in its statement announcing Byron's resignation he had not made a statement himself. Tangent
In the days since last week's Coldplay concert, several high-profile artists have poked fun at the incident at their own shows. Oasis frontman Liam Gallagher said at a concert in England on Sunday: 'Don't worry, we ain't got any of that Coldplay, snidey fucking camera sh—. It doesn't matter to us who you're f—ing mingling with.' Country star Morgan Wallen joked at an Arizona concert Friday that anyone who is 'here with their side chick or whatever' is 'safe.' During a concert in South Carolina on Thursday, Luke Bryan joked: 'We're gonna shine our cameras on anybody.' Coldplay acknowledged the scandal at a concert in Madison, Wisconsin, on Saturday. 'We'd like to say hello to some of you in the crowd. How we're gonna do that is we're gonna use our cameras and put some of you on the big screen,' Martin said, to laughs from the crowd.
Astronomer CEO Steps Down After Being Seen Embracing HR Chief On Coldplay Kiss Cam (Forbes)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Mike Rowe says US in a ‘modern-day Manhattan project' after scrapping shop class — is it time to ditch your desk job?
With billions of dollars pouring in to fuel America's contributions to the ongoing Artificial Intelligence race, Mike Rowe believes we are living through what he calls a 'modern-day Manhattan Project.' However, America's AI efforts face their own set of hurdles, including a lack of skilled tradespeople to build the energy and data center infrastructure needed to power AI. Don't miss Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how I'm 49 years old and have nothing saved for retirement — what should I do? Don't panic. Here are 6 of the easiest ways you can catch up (and fast) You don't have to be a millionaire to gain access to this $1B private real estate fund. In fact, you can get started with as little as $10 — here's how 'When we took shop class out of high school, we sent a pretty clear message to the workforce," Rowe, the host of Dirty Jobs, told Fox News. "We put our thumb on the scale, we made a real judgement call. Consequently, we have 7.6 million open jobs right now in those [skilled labor] fields.' And Rowe isn't the only one ringing this alarm bell. Nobel laureate Geoffrey Hinton — often called the 'Godfather of AI' — also recommended blue collar skills as a way to prepare for the age of automation. 'I'd say it's going to be a long time before [AI] is as good at physical manipulation as us, and so a good bet would be to be a plumber,' Hinton said on The Diary of a CEO podcast. As more experts urge Americans to rethink their career paths, could now be the moment to consider rolling up your sleeves and going to trade school? Here's what you need to know. The pros Perhaps the best reason to consider a career in the trades is the projected shortage of skilled labor workers in the near future. Nearly 1.9 million manufacturing jobs could go unfilled over the next decade, according to a study from the Manufacturing Institute and Deloitte. Meanwhile, America could be short about 550,000 plumbers by 2027, according to The Hill. Put simply, there's growing demand for blue collar workers while white collar staffers face dwindling demand and potential layoffs. As a consequence, skilled trade workers have more bargaining power to achieve better wages. Between 2020 and 2024, average wages across the skilled trades sectors grew 20%, according to McKinsey & Company. Experienced electricians, elevator installers, construction managers and HVAC technicians can earn $100,000 or more per year, according to the Philadelphia Technician Training Institute. And the fact that these trades do not require an advanced college degree also reduces the burden on young people willing to acquire these skills. Trade schools are relatively inexpensive, and organizations such as Rowe's mikeroweWORKS Foundation have helped thousands of young professionals achieve six-figure salaries without taking on massive student debt. However, before you ditch your cubicle for a construction site, it's worth considering some of the drawbacks of this bold career move. Read more: Want an extra $1,300,000 when you retire? Dave Ramsey says — and that 'anyone' can do it The Cons Being a blue collar worker could be lucrative, but only after you've gained sufficient skills and experience. For instance, the average apprenticeship for construction workers could be slightly longer than four years, according to the American Apprenticeship Initiative. Making matters worse, your earnings are likely to start relatively low during your apprenticeship, which means it could be several years before you crack the six-figure threshold. Another disadvantage with blue collar work is that it is highly physical and may be better suited for younger workers. Mining, construction and agricultural workers have relatively high rates of workplace injuries, according to the AFL-CIO. These risks are higher for older workers, which could push tradespeople to consider earlier retirement than their white collar peers. Finally, the current lack of automation in the trades might be temporary. Several tech giants and startups are working on humanoid robots and there are already prototypes of autonomous machines for construction, as well as shipbuilding and welding. Amazon already has roughly a million robots in its warehouses and the company's workforce could be more robotic than human in the near future, according to the Wall Street Journal. The bottom line There are plenty of advantages and disadvantages to switching your career to the trades. If you're young and enthusiastic about gaining hands-on experience, this could be the right move. But if you've already built soft skills over several years and don't find physical labor enjoyable, this might not be the best move for you. What to read next Robert Kiyosaki warns of a 'Greater Depression' coming to the US — with millions of Americans going poor. But he says these 2 'easy-money' assets will bring in 'great wealth'. How to get in now Accredited investors can now buy into this $22 trillion asset class once reserved for elites – and become the landlord of Walmart, Whole Foods or Kroger without lifting a finger. Here's how Rich, young Americans are ditching the stormy stock market — here are the alternative assets they're banking on instead Here are 5 'must have' items that Americans (almost) always overpay for — and very quickly regret. How many are hurting you? Stay in the know. Join 200,000+ readers and get the best of Moneywise sent straight to your inbox every week for free. This article provides information only and should not be construed as advice. It is provided without warranty of any kind. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Six Flags to Announce 2025 Second Quarter Results on Aug. 6, 2025; Earnings Call Starts at 10 AM EDT
CHARLOTTE, N.C., July 28, 2025--(BUSINESS WIRE)--Six Flags Entertainment Corporation (NYSE: FUN), the largest regional amusement park operator in North America, said today it will issue 2025 second-quarter results in the pre-market hours of Wednesday Aug. 6, 2025. Starting at 10 a.m. EDT that day, Six Flags management will host a conference call with the investment community to provide additional details regarding second-quarter results and discuss the Company's business outlook. Management participants on the call will include Six Flags CEO Richard Zimmerman and CFO Brian Witherow. Investors and all other interested parties can access a live, listen-only audio webcast of the call on the Six Flags investor website under the tabs Investor Information / Events & Presentations. Those unable to listen to the live webcast can visit our investor website shortly after the call's conclusion to access a recorded version of the call. ABOUT SIX FLAGS ENTERTAINMENT CORPORATION Six Flags Entertainment Corporation (NYSE: FUN) is North America's largest regional amusement-resort operator with 27 amusement parks, 15 water parks and nine resort properties across 17 states in the U.S., Canada and Mexico. Focused on its purpose of making people happy, Six Flags provides fun, immersive and memorable experiences to millions of guests every year with world-class coasters, themed rides, thrilling water parks, resorts and a portfolio of beloved intellectual property such as Looney Tunes®, DC Comics® and PEANUTS®. This news release and prior releases are available under the News tab at View source version on Contacts Investor Contact: Michael Russell, 419.627.2233 Media Contact: Gary Rhodes, 704.249.6119 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival ('PFS') Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial
Hazard Ratios and Improvements in Median PFS areUnprecedented in HR+/HER2- Advanced Breast Cancer ('ABC') Gedatolisib + palbociclib + fulvestrant ('gedatolisib triplet') reduced the risk of disease progression or death by 76% vs. fulvestrant (HR=0.24; 95% CI: 0.17–0.35; p<0.0001). Median PFS was 9.3 months with the gedatolisib triplet versus 2.0 months with fulvestrant Gedatolisib + fulvestrant ('gedatolisib doublet') reduced the risk of progression or death by 67% vs. fulvestrant (HR=0.33; 95% CI: 0.24–0.48; p<0.0001). Median PFS was 7.4 months with the gedatolisib doublet versus 2.0 months with fulvestrant The efficacy results establish several new milestones in the history of drug development for HR+/HER2- advanced breast cancer Treatment discontinuation due to a treatment-related adverse event for the gedatolisib triplet and gedatolisib doublet was lower than was observed in Arm D of Celcuity's Phase 1b trial in ABC patients and lower than observed in any Phase 3 trials for currently approved drug combinations in HR+/HER2- ABC The favorable safety profile with the gedatolisib triplet and gedatolisib doublet was better than observed in the Phase 1b trial in ABC, including lower rates of hyperglycemia and stomatitis Full data from the PIK3CA wild-type cohort of the VIKTORIA-1 clinical trial will be presented at an upcoming medical conference later this year. Celcuity expects to submit a New Drug Application for gedatolisib to the U.S. Food and Drug Administration in the fourth quarter of 2025. Topline data for the VIKTORIA-1 PIK3CA mutation cohort is expected by the end of 2025. Management to host webcast and conference call today, July 28, 2025, at 8:00 a.m. ET MINNEAPOLIS, July 28, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced positive topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestrant with and without palbociclib versus fulvestrant in adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA wild-type, locally advanced or metastatic breast cancer, following progression on, or after, treatment with a CDK4/6 inhibitor and an aromatase inhibitor. In the trial, the gedatolisib triplet demonstrated a statistically significant and clinically meaningful improvement in PFS among patients, reducing the risk of disease progression or death by 76% compared to fulvestrant (based on a hazard ratio [HR] of 0.24, 95% confidence interval [CI] 0.17-0.35; p<0.0001). The mPFS, as assessed by blinded independent central review ('BICR'), was 9.3 months with the gedatolisib triplet versus 2.0 months with fulvestrant, an incremental improvement of 7.3 months. The gedatolisib doublet also demonstrated a statistically significant and clinically meaningful improvement in PFS among patients, reducing the risk of disease progression or death by 67% compared to fulvestrant (HR of 0.33, 95% CI 0.24-0.48; p<0.0001). The mPFS, as assessed by BICR, was 7.4 months with the gedatolisib doublet versus 2.0 months with fulvestrant, an incremental improvement of 5.4 months. The topline efficacy data from the VIKTORIA-1 PIK3CA wild-type cohort established several new milestones in the history of drug development for HR+/HER2- advanced breast cancer: The hazard ratios for the gedatolisib triplet and doublet are more favorable than have ever been reported by any Phase 3 trial for patients with HR+/HER2- ABC. The 7.3- and 5.4-months incremental improvements in median PFS for the gedatolisib triplet and gedatolisib doublet over fulvestrant, respectively, are higher than have ever been reported by any Phase 3 trial for patients with HR+/HER2- ABC receiving at least their second line of therapy. Gedatolisib is the first inhibitor targeting the PI3K/AKT/mTOR pathway to demonstrate positive Phase 3 results in patients with HR+/HER2-/PIK3CA wild-type ABC whose disease progressed on or after treatment with a CDK4/6 inhibitor. Sara Hurvitz, MD, Senior Vice President, Clinical Research Division, Fred Hutchinson Cancer Center, Professor and Head, Division of Hematology and Oncology, University of Washington, Department of Medicine and co-principal investigator for the trial said: 'Patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer whose disease has progressed while on, or after, treatment with a CDK4/6 inhibitor typically derive limited benefit from subsequent endocrine-based therapy. The topline data for both gedatolisib regimens from VIKTORIA-1 are potentially practice-changing. To my knowledge, we have not seen Phase 3 results in patients with HR-positive, HER2-negative advanced breast cancer before where there was a quadrupling of the likelihood of survival without disease progression relative to the study control.' Treatment discontinuation due to a treatment-related adverse event for the gedatolisib triplet and gedatolisib doublet was lower than was observed in Arm D of the Phase 1b trial in patients with ABC, and lower than observed in any Phase 3 trials for currently approved drug combinations in HR+/HER2- ABC. Additionally, the gedatolisib triplet and gedatolisib doublet were better tolerated than was observed in the Phase 1b trial in patients with ABC, including lower rates of hyperglycemia and stomatitis. Igor Gorbatchevsky, MD, Chief Medical Officer of Celcuity said: 'The topline data from VIKTORIA-1 demonstrate the potential for gedatolisib to become a transformative new medicine for the treatment of patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer whose disease progressed on or after treatment with CDK4/6 inhibitors. The 7.3 and 5.4-months incremental improvement in median PFS relative to fulvestrant for the gedatolisib regimens are potentially paradigm shifting results. We are also very excited that treatment with gedatolisib combined with fulvestrant with or without palbociclib was well-tolerated by the VIKTORIA-1 patients and that only a few patients discontinued treatment due to an adverse event.' Brian Sullivan, Chairman, Chief Executive Officer and co-founder of Celcuity said, 'The efficacy improvement relative to the control that each of the gedatolisib regimens demonstrated was historic for this patient population. We are excited about the potential opportunity to provide a breakthrough therapeutic option for patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.' Full data from the PIK3CA wild-type cohort of the VIKTORIA-1 clinical trial will be presented at an upcoming medical conference later this year. Celcuity expects to submit a New Drug Application for gedatolisib to the U.S. Food and Drug Administration in the fourth quarter of 2025. Topline data for the VIKTORIA-1 PIK3CA mutation cohort is expected by the end of 2025. Webcast and Conference Call InformationThe Celcuity management team will host a webcast/conference call on Monday, July 28, 2025, at 8:00 a.m. ET to discuss the topline results from the Phase 3 VIKTORIA-1 trial. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. A replay of the webcast will be available on the Celcuity website following the live event. Notes HR+/HER2- Breast cancer Breast cancer is the second most common cancer and one of the leading causes of cancer-related deaths worldwide.1 More than two million breast cancer cases were diagnosed globally in 2022.1 While survival rates are high for those diagnosed with early breast cancer, only approximately 30% of patients who are diagnosed with or who progress to metastatic disease are expected to live five years after their diagnosis.2 HR+/HER2- breast cancer is the most common subtype of breast cancer, accounting for approximately 70% of all breast cancers.2 Three interconnected signaling pathways, estrogen, cyclin D1-CDK4/6, and PI3K/AKT/mTOR (PAM), are primary oncogenic drivers of HR+, HER2- breast cancer.3 Therapies inhibiting these pathways are approved and used in various combinations for advanced breast cancer. Currently approved inhibitors of the PAM pathway for breast cancer target a single PAM pathway component, such as PI3Kα, AKT, or mTORC1.4,5,6,7 However, resistance to CDK4/6 inhibitors and current endocrine therapies develops in many patients with advanced disease.8 Survival rates are low with 30% of patients anticipated to live beyond five years after diagnosis.2 Optimizing the inhibition of the PAM pathway is an active area of focus for breast cancer research. VIKTORIA-1VIKTORIA-1 is a Phase 3 open-label, randomized clinical trial to evaluate the efficacy and safety of gedatolisib in combination with fulvestrant with or without palbociclib in adults with HR+/HER2- ABC whose disease progressed on or after prior CDK4/6 therapy in combination with an aromatase inhibitor. The clinical trial is enrolling subjects regardless of PIK3CA status while enabling separate evaluation of subjects according to their PIK3CA status. Subjects who meet eligibility criteria and do not have confirmed PI3KCA mutations (WT) were randomly assigned (1:1:1) to receive a regimen of either gedatolisib, palbociclib, and fulvestrant, gedatolisib and fulvestrant, or fulvestrant. Subjects who meet eligibility criteria and have confirmed PI3KCA mutations (MT) are randomly assigned (3:3:1) to receive a regimen of either the gedatolisib triplet, alpelisib and fulvestrant, or the gedatolisib doublet. GedatolisibGedatolisib is an investigational, multi-target PAM inhibitor that potently targets all four class I PI3K isoforms, mTORC1, and mTORC2 to induce comprehensive blockade of the PAM pathway.9,10,11 As a multi-target PAM inhibitor, gedatolisib's mechanism of action is highly differentiated from currently approved single-target inhibitors of the PAM pathway.11 Inhibition of only a single PAM component gives tumors an escape mechanism through cross-activation of the uninhibited targets. Gedatolisib's comprehensive PAM pathway inhibition ensures full suppression of PAM activity by eliminating adaptive resistance cross-activation that occurs with single-target inhibitors. Unlike single-target inhibitors of the PAM pathway, gedatolisib has demonstrated equal potency and comparable cytotoxicity in PIK3CA-mutant and -wild-type breast tumor cells in nonclinical studies and early clinical data.11,12 About CelcuityCelcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about Celcuity's active clinical trials can be found at Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at Follow us on LinkedIn and X. Forward-Looking StatementsThis press release contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements relating to the potential therapeutic benefits of gedatolisib; the size, design and timing of our clinical trials; our interpretation of topline clinical trial data; the ability of our data to support the filing of an NDA with the FDA; our expectations regarding the timing of and our ability to obtain FDA approval to commercialize gedatolisib; and other expectations with respect to gedatolisib. Words such as, but not limited to, 'look forward to,' 'believe,' 'expect,' 'anticipate,' 'estimate,' 'intend,' "confidence," "encouraged," 'potential,' 'plan,' 'targets,' 'likely,' 'may,' 'will,' 'would,' 'should' and 'could,' and similar expressions or words identify forward-looking statements. The forward-looking statements included in this press release are based on management's current expectations and beliefs which are subject to a number of risks, uncertainties and factors, including that our topline results are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial; unforeseen delays in our planned NDA for gedatolisib; and our ability to obtain and maintain regulatory approvals to commercialize gedatolisib. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2024, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as such risks may be updated in our subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by these cautionary statements, and we undertake no obligation to revise or update this press release to reflect events or circumstances after the date hereof. References: Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;10.3322/caac.21660. National Cancer Institute. Surveillance, Epidemiology and End Results Program (Accessed July 2025). Alves, C. L., & Ditzel, H. J. Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. Int J Mol Sci, 2023;24(5),4522. United States Package Insert, US FDA, ITOVEBI United States Package Insert, US FDA, PIQRAY United States Package Insert, US FDA, TRUCAP United States Package Insert, US FDA, AFINITOR Lloyd M R, et al. Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. Clin Cancer Res. 2022;28(5):821-30 Venkatesan, A. M., et al. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem, 2010;53(6), 2636-2645. Mallon, R., et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin Cancer Res, 2011;17(10), 3193-3203. Rossetti, S., et al. Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models. NPJ Breast Cancer, 2024;10(1), 40. Layman, R., et al. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. Lancet Oncol, 2024;25(4), 474-487. View source version of release on Contacts: Celcuity Inc. Brian Sullivan, bsullivan@ Vicky Hahne, vhahne@ (763) 392-0123 ICR HealthcarePatti Bank, (415) 513-1284Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
